Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model

Cancer Letters

Volumn 165, Issue 2, 2001, Pages 161-170

  Alves, Frauke ^a   Borchers, Ulrich ^a   Padge, Björn ^a   Augustin, Hellmut ^a   Nebendahl, Klaus ^a   Klöppel, Günter ^b   Tietze, Lutz F ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Antioncogenic therapy; Matrix metalloproteinase inhibitor; Pancreatic ductal adenocarcinoma; Preclinical animal tumor model; Prinomastat; Tumor spread

Indexed keywords

ANTIMETASTATIC AGENT; METALLOPROTEINASE INHIBITOR; PRINOMASTAT;

ABDOMEN; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG; MALE; METASTASIS; MICROVASCULATURE; MOUSE; NECROSIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; SCID MOUSE; TUMOR GROWTH; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL DIFFERENTIATION; FEMALE; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, SCID; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; ORGANIC CHEMICALS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0035953861     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00420-7     Document Type: Article

References (37)

1. Pancreatic cancer: Clinical presentation, pitfalls and early clues
2. Extrinsic regulators of epithelial tumor progression: Metalloproteinases
3. Matrix-metalloproteinases 1, 2, 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: An in situ hybridization study
4. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
5. Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas
6. Role of MT-MMPs and MMP2 in pancreatic cancer progression
7. Reduced angiogenesis and tumor progression in gelatinase-A deficient mice
8. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
9. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
10. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
11. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
12. The matrix metalloproteinase inhibitor batimastat (BB94) retards human breast cancer solid tumor growth but not ascites formation in nude mice
13. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
14. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth and decreases mortality and tumorigenesis in vivo
15. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer
16. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
17. Broad antitumor and antiangiogenic activities of AG3340, a potent MMP inhibitor undergoing advanced oncology clinical trials
18. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
19. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
20. Inhibitors of angiogenesis enter phase III testing
21. Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related disease
22. Ongoing trials with matrix metalloproteinase inhibitors
23. p53 and K-RAS alterations in pancreatic epithelial lesions
24. Evidence of functional lymphocytes in some (leaky) scid mice
25. Structure-based design of MMP inhibitors: Discovery and development of PRINOMASTAT
26. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: Classical and random mitotic activity assessments with correction for volume percentage of epithelium
27. An approximate distribution of estimates of variance components
28. A novel 'patient-like' treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice
29. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4
30. A clinical nude mouse metastatic model for highly malignant pancreatic cancer
31. Therapy of human carcinoma implants by iriotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages
32. An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade
33. Changing views of the role of matrix metalloproteinases in metastasis
34. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma
35. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer
36. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts
37. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer